Multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of a pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort: iPHARMGx TRANSPGx nested clinical trial.

doi:10.1136/bmjopen-2025-109279

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of a pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort: iPHARMGx TRANSPGx nested clinical trial.

BMJ open - 3 Aug 2026

Seco-Meseguer Enrique, Stewart Stefan, Diago-Sempere Elena, Jiménez Carlos, Macías Carmona Nicolas, Fernández Solís Juan, Vila Santandreu Anna, Valero San Cecilio Rosalía, López Jiménez Verónica, Carmona-Rodríguez Montserrat, López-Fernández Luis A, Imaz-Iglesia Iñaki, García-Saiz María Del Mar, Farré Magí, Rodriguez-Jimenez Consuelo, Sanabria-Cabrera Judith, Rosas-Alonso Rocío, García-García Irene, Borobia Alberto M

Abstract excerpt

INTRODUCTION: Genetic variations impact drug response, driving the need for personalised medicine through pre-emptive pharmacogenetic testing. However, the adoption of pre-emptive pharmacogenetic testing for commonly prescribed drugs, such as tacrolimus, outside of tertiary hospitals is limited due to a lack of pharmacoeconomic evidence to support widespread implementation by healthcare policymakers. The iPHARMGx...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Graft Rejection

Share to Multicenter Studies as Topic

Share to Pharmacogenomic Testing

Share to Randomized Controlled Trials as Topic

Share to Renal Insufficiency, Chronic

Share to Single-Blind Method

Share to Tacrolimus

Source

Open in PubMed Open full text

Identifiers

PMID: 42547238
DOI: 10.1136/bmjopen-2025-109279
PMCID: PMC13435983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of a pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort: iPHARMGx TRANSPGx nested clinical trial.PMID 42547238Read ↗

Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial.Semantic proximity Read ↗

Protocol for Bayesian combined multi-genotype and concentration informed tacrolimus dosing in paediatric solid organ transplantation (BRUNO-PIC)Semantic proximity Read ↗

Clinical Impact of the Adaptation of Initial Tacrolimus Dosing to the CYP3A5 Genotype After Kidney Transplantation: Systematic Review and Meta-Analysis of Randomized Controlled Trials.Semantic proximity Read ↗

Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations.Semantic proximity Read ↗

Evaluating the evidence for genotype-informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review.Semantic proximity Read ↗

A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction.Semantic proximity Read ↗

Tacrolimus dosing in liver transplant recipients using phenotypic personalized medicine: A phase 2 randomized clinical trial.Semantic proximity Read ↗

CYP3A5 genotyping-guided dosing versus weight-based dosing in a multi-ethnic population of kidney transplant recipientsSemantic proximity Read ↗

Genotype Informed Bayesian Dosing of Tacrolimus in Paediatric Solid Organ Transplant IndividualsSemantic proximity Read ↗

Pharmacogenomics in kidney transplant recipients and potential for integration into practice.Semantic proximity Read ↗

Estimation of the benefit from pre-emptive genotyping based on the nationwide cohort data in South Korea.Semantic proximity Read ↗

Machine learning-based method for tacrolimus dose predictions in Chinese kidney transplant perioperative patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.